Health-care companies fell sharply as ebullience about a new class of weight control drugs subsided.
Viking Therapeutics shares gave back some of their recent gains amid skepticism about the biotech firm's attempt to compete with heavyweights such as Novo Nordisk on obesity drugs. Novo Nordisk fell, shaving its gains for the year to date to around 25%.
Shares of Eiger BioPharmaceuticals plunged after the drug developer filed for chapter 11 bankruptcy with a deal in hand to sell its Zokinvy drug.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
04-01-24 1751ET
